nabilone (Cesamet)
Jump to navigation
Jump to search
Introduction
Tradename: Cesamet, DEA-controlled substance: class 2
Indications
- 2nd line agent for nausea/vomiting from chemotherapy
- may improve symptoms of agitation & aggression among patients with Alzheimer's disease*[2]
- may improve anxiety & sleep disorders in Parkinson disease[3]
* see psychosis & agitation in the elderly
Dosage
Tabs: 1 mg (bottles of 20)
Adverse effects
- orthostatic hypotension
- dizziness
- drowsiness
- dry mouth
- euphoria
- coordination disturbance
Drug interactions
- may produce additive effects with CNS depressants
- may displace highly protein bound drugs
- may cause additive tachycardia &/or hypertension when used in combination with anticholinergics, tricyclic antidepressants, or sympathomimetic agents
Mechanism of action
- interaction with cannabinoid receptor(s) in CNS
More general terms
References
- ↑ Prescriber's Letter 13(8): 2006 New Drug: Cesamet (Nabilone) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220813&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Monaco K Nabilone Effective for Easing Agitation in Alzheimer's - Cognition, neuropsychiatric symptoms also improved with synthetic cannabinoid. MedPage Today. July 25, 2018 https://www.medpagetoday.com/meetingcoverage/aaic/74214
Lanctot K, et al Nabilone significantly improves agitation/aggression in patients with moderate-to-severe AD: Preliminary results of a placebo- controlled, double-blind, cross-over trial. Alzheimer's Association International Conference (AAIC) 2018; Abstract F4-02-04. - ↑ 3.0 3.1 Peball M, Krismer F, Knaus HG et al. Non-motor symptoms in Parkinson's disease are reduced by nabilone. Ann Neurol 2020 Aug 5; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32757413 https://onlinelibrary.wiley.com/doi/10.1002/ana.25864
- ↑ Valeant Pharmaceuticals International http://www.valeant.com